Xyrem
Total Payments
$12.2M
Transactions
21,224
Doctors
5,074
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $6.2M | 10,233 | 3,446 |
| 2017 | $5.9M | 10,991 | 3,524 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.8M | 450 | 72.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 617 | 13.6% |
| Consulting Fee | $499,591 | 133 | 4.1% |
| Travel and Lodging | $493,424 | 1,489 | 4.1% |
| Food and Beverage | $475,020 | 18,372 | 3.9% |
| Grant | $201,586 | 5 | 1.7% |
| Education | $5,328 | 158 | 0.0% |
Payments by Type
Research
$8.8M
450 transactions
General
$3.3M
20,774 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of Xyrem with an open-label pharmacokinetic evaluation and safety extension in pediatric subjects with narcolepsy with cataplexy | Jazz Pharmaceuticals Inc. | $3.6M | 1 |
| A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open-Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy | Jazz Pharmaceuticals Inc. | $3.6M | 0 |
| A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $661,892 | 2 |
| PSG Biomarkers Narcolepsy Detector | Jazz Pharmaceuticals Inc. | $388,889 | 0 |
| A randomized double-blind controlled bicentric study comparing the efficacy and tolerance of sodium oxybate in patients affected with idiopathic hypersomnia | Jazz Pharmaceuticals Inc. | $143,909 | 0 |
| A MULTICENTER RETROSPECTIVE AND PROSPECTIVE FOLLOW-UP STUDY OF EARLY ONSET CHILDHOOD NARCOLEPSY RECENT CASES AND POST INFECTION HUMAN SUBJECTS | Jazz Pharmaceuticals Inc. | $134,891 | 0 |
| Open-label clinical trial to evaluate the efficacy od sodium oxybate in the treatment of two under-recognized clinical conditions post-traumatic narcolepsy and post-traumatic hypersomnia | Jazz Pharmaceuticals Inc. | $106,666 | 0 |
| Open-label clinical trial to evaluate the efficacy of sodium oxybate Xyrem in the treatment of two under-recognized clinical conditions post-traumatic narcolepsy and post-traumatic hypersomnia -subjective | Jazz Pharmaceuticals Inc. | $86,307 | 0 |
| Characterization, Evolution and Neuropsychological Effects of Disturbed Nocturnal Sleep DNS in Children with Narcolepsy | Jazz Pharmaceuticals Inc. | $55,784 | 0 |
| Central mechanisms and treatment response of sodium oxybate in spasmodic dysphonia and voice tremor | Jazz Pharmaceuticals Inc. | $8,066 | 0 |
| The fundamental role of slow-wave sleep after brain injury. | Jazz Pharmaceuticals Inc. | $4,315 | 0 |
| Understanding the mechanisms underlying the positive effects of SXB on sleep slow waves | Jazz Pharmaceuticals Inc. | $4,315 | 0 |
Top Doctors Receiving Payments for Xyrem — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Cardiovascular Disease | Williamston, NC | $5,546 | 17 |
| , M.D | Sleep Medicine | Grand Rapids, MI | $5,434 | 18 |
| , M.D | Sleep Medicine | Boston, MA | $5,420 | 2 |
| , D.O | Pulmonary Disease | Lansdale, PA | $5,404 | 42 |
| , M.D | Neurology | El Cerrito, CA | $5,177 | 6 |
| , D.O | Family Medicine | Follansbee, WV | $5,071 | 25 |
| , MD | Sleep Medicine | San Diego, CA | $5,028 | 12 |
| , M.D | Sleep Medicine | Kansas City, MO | $4,982 | 12 |
| , MD | Pediatric Pulmonology | Winter Park, FL | $4,953 | 13 |
| , M.D | Internal Medicine | Palo Alto, CA | $4,950 | 5 |
| , M.D | Neurology | Nashville, TN | $4,658 | 11 |
| , M.D | Psychiatry | Rockville, MD | $4,315 | 6 |
| , MD | Pulmonary Disease | Miles City, MT | $4,147 | 6 |
| , M.D | Pulmonary Disease | Saint Louis, MO | $3,831 | 11 |
| , M.D | Pulmonary Disease | Austin, TX | $3,811 | 93 |
| , M.D | Internal Medicine | New Haven, CT | $3,600 | 1 |
| , M.D | Pediatrics | Bluefield, WV | $3,526 | 28 |
| , MD | Family Medicine | Tulsa, OK | $3,503 | 31 |
| , MD | Internal Medicine | Seattle, WA | $3,324 | 3 |
| , M.D | Pulmonary Disease | West Haven, CT | $3,150 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $2,735 | 7 |
| , M.D | Sleep Specialist, PhD | Baton Rouge, LA | $2,649 | 6 |
| , M.D | Sleep Medicine | Dallas, TX | $2,555 | 20 |
| , M.D | Pulmonary Disease | Miami Beach, FL | $2,546 | 6 |
| , M.D., PH.D | Neurology | New Albany, OH | $2,076 | 6 |
Ad
Manufacturing Companies
- Jazz Pharmaceuticals Inc. $12.2M
Product Information
- Type Drug
- Total Payments $12.2M
- Total Doctors 5,074
- Transactions 21,224
About Xyrem
Xyrem is a drug associated with $12.2M in payments to 5,074 healthcare providers, recorded across 21,224 transactions in the CMS Open Payments database. The primary manufacturer is Jazz Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $6.2M was paid across 10,233 transactions to 3,446 doctors.
The most common payment nature for Xyrem is "Unspecified" ($8.8M, 72.6% of total).
Xyrem is associated with 12 research studies, including "A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of Xyrem with an open-label pharmacokinetic evaluation and safety extension in pediatric subjects with narcolepsy with cataplexy" ($3.6M).